Lantern Pharma and Oregon partner to develop cancer treatment
Lantern Pharma has entered into a partnership with Oregon Therapeutics for optimising the development of the cancer drug candidate, XCE853, through an AI-driven approach. XCE853 is an inhibitor of protein disulfide isomerase (PDI). The partnership will …